Life Science companies face major challenges to continued operations and profitability including patent expirations, low R&D productivity, increased competition, decreased margins, non-optimized processes, and mounting compliance pressure. Join us May 25th at 11am EDT to understand the technologies needed to meet today’s requirements, how to spend more time on science and less time correcting data, and how to improve efficiencies in process development, collaboration, and product quality.
iEnzyme-Linked Immunosorbent Assays (ELISAs) to monitor host cell protein levels are challenging. This article illustrates an enhanced anti-host cell protein antibody coverage analysis method solution.
Achieving consistent cell growth is critically important to the biotech industry. To optimize the final drug product output the current industry trends are towards higher cell densities and protein titers.
Scott Cleve brings an entire career dedicated to the mastery of global biopharma regulatory standards to his role as VP of Regulatory Operations and Compliance at bluebird bio. Cleve joins the Business of Biotech to discuss the regulatory trends shaping bluebird's pipeline of gene therapies for the treatment of serious, life-altering diseases. Listen now and subscribe so you never miss an episode.